Insulin-like growth factor I (IGF-I) stimulates hematopoiesis. We examined whether bone marrow stromal cells synthesize IGF-I. Secretion of IGF-I immunoreactivity by cells from TC-1 murine bone marrow stromal cells was time-dependent and inhibited by cycloheximide. Gel filtration chromatography under denaturing conditions of TC-1 conditioned medium demonstrated two major peaks of apparent IGF-I immunoreactivity with molecular weights of -7.5-8.0 kD, the size of native IGF-I, and > 25 kD. Expression of IGF-I mRNA was identi- 
Introduction
Insulinlike growth factor (IGF-I)'/somatomedin-C is a mitogenic polypeptide structurally homologous with proinsulin (1) . IGF-I, through its interaction with specific IGF-I receptors, mediates many of the growth-promoting effects of growth hormone (2) . Although hepatic production of IGF-I appears to account for the majority of circulating IGF-I, it is also produced in a wide variety of extrahepatic tissues (3, 4) . In addition, cells of mesenchymal origin such as fibroblasts (5, 6) , smooth muscle cells (5) , glomerular mesangial cells (7) , and fat-storing cells of the liver (8) synthesize IGF-I in vitro. These cell types also possess IGF-I receptors (5) (6) (7) (8) . These findings suggest that IGF-I is not simply an endocrine hormone, but may also act through autocrine or paracrine mechanisms, having its biologic action at or near the site of origin (9, 10) . The response of cells to IGF-I can be modulated by specific IGF binding proteins (IGFBP), which have been detected in plasma, body fluids, as well as in medium conditioned by several primary cell cultures and organ explants (1, 1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Regulation of hematopoiesis is a complex process that involves both multilineage and lineage-specific growth factors (18) (19) (20) . IGF-I stimulates erythroid and granulocytic colony formation (21) (22) (23) (24) . Recently, clonal culture techniques have demonstrated that the growth-promoting effects of growth hormone on erythroid and granulocytic progenitors is mediated indirectly in a paracrine fashion, via IGF-I (22, 23) . Whereas IGF-I may be delivered by the serum, it is likely that IGF-I is synthesized within the marrow. However, the cells responsible for the production of IGF-I in the marrow microenvironment have not been precisely identified. Macrophages constitute a potential candidate, because the U937 macrophage cell line and alveolar macrophages, members of the monocyte-phagocyte system of bone marrow-derived cells, have been shown to synthesize . In addition, T-lymphoblast cell lines also synthesize . Bone marrow stromal cells play an important role in the regulation of hematopoiesis through direct cell-cell interaction and the release ofcytokines (26, 27) . Cultured murine TC-1 stromal cells, which elaborate several cytokines such as granulocyte-macrophage colony stimulating factor (GM-CSF), constitute a useful model system to study the production of other hematopoietic regulatory peptides such as IGF-I (28, 29) .
We have characterized IGF-I immunoreactivity in culture medium from TC-I cells and identified their expression of IGF-I mRNA. Our results indicate that TC-l cells secrete both IGF-I and three IGFBP species of 31, 38, and 40 kD.
penicillin 100 U/ml, streptomycin 100 Ag/ml, nystatin 25 ng/ml, and 17% FCS (HyClone Laboratories, Inc., Logan, UT), and incubated at 370C in 5% CO2. Cells grown to confluence were passed weekly by exposure to 0.1% Trypsin (Gibco Laboratories). Cells from passages 35-42 were used.
Cells were plated into 12-well dishes, allowed to reach confluence, washed twice with serum-free, insulin-free Fischer's medium and incubated overnight in the same medium. This medium was then discarded and fresh serum-free, insulin-free medium was added. Conditioned medium was collected after 8, 24, and 48 h and cell-free supernatants were stored at -70'C for RIA. In Recovery of the applied radioactivity was > 90%. Fractions were assayed for IGF-I immunoreactivity. RNase protection assay for IGF-I mRNA. RNA from confluent TC-I and TC-I -C-1I cells was extracted with guanidinium isothiocyanate, isolated by centrifugation through cesium chloride extracted with phenol/chloroform, precipitated with ethanol, and stored in water at -70°C (30, 31) . Poly(A)+ was prepared by oligo(dT)-cellulose affinity chromatography (30, 31 and the reaction mixture was extracted and precipitated. This synthesized RNA probe (I X 106 cpm) was hybridized to TC-1 poly(A)+ RNA in 80% formamide/10 mM Pipes/400 mM NaCl/I mM EDTA for 12 h at 50°C. After hybridization, the reaction mixture was digested sequentially with RNases A (50 Mg/ml) and T1 (2 ug/ml) and then proteinase K (0.16 mg/ml). The products were analyzed by electrophoresis through a 7 M urea/6% acrylamide gel, followed by autoradiography (33) .
Reverse transcription PCR analysis ofIGF-I mRNA. RNA was reverse transcribed using an anti-sense primer from IGF-I exon 3 (5'-C-l-lCTGAGTC T-T GGGCATGTCAGT-3'). After the addition of sense primer from IGF-I exon 2 (5'-GACCCTTITGCGGGGCT-GAGCTGGT-3') the sample was heated at 940C for 5 min. Amplification of cDNA was carried out with the Perkin Elmer Cetus Gene Amp kit (Norwalk, CT) according to the specifications of the manufacturer in a M. J. Research, Inc. thermal cycler (Watertown, MA) (19) . The first six cycles involved denaturation at 940C for 1 min, primer annealing at 550C for 1.5 min, and extension at 720C for 2 min. Further amplification was performed for 26 additional cycles, each cycle involving denaturation at 940C for 1 min, primer annealing at 60'C for 1.5 min, and extension at 720C for 2.5 min. After a total of 32 cycles, the reaction product was subjected to gel electrophoresis on 2% agarose and stained with ethidium bromide (30, 31) . The predicted amplified DNA is a 250-bp fragment.
Charcoal adsorption assay for IGF-binding activity. IGF binding activity was measured using a modification of Martin and Baxter (8, 34) . Triplicate aliquots of conditioned media were incubated with
[1251]-IGF-I in 500 Ml of 50 mM Tris-HCI, 0.1% BSA (Sigma Chemical Co., St. Louis, MO), pH 7.4. After 2 h incubation at room temperature, 1% activated charcoal (Sigma Chemical Co.) without protamine was added to the samples followed by incubation for 15 min and centrifugation at 4VC. Aliquots of supernatant containing protein bound [1251_ IGF-I were counted. Nonconditioned medium was assayed in parallel and was subtracted from total bound radioactivity to determine specific binding activity. Displacement curves were generated by coincubation with dilutions of unlabeled human IGF-I and rat IGF-II (multiplication stimulating activity), obtained from Collaborative Research Inc. (Lexington, MA), or bovine insulin (Sigma Chemical Co.). Aliquots of selected fractions from the gel filtration column were assayed in duplicate. The final concentration of guanidine-HC1 was 0.06 M. Equal amounts ofgel filtration column buffer were assayed in parallel and subtracted from total bound radioactivity to determine specific binding.
Western Blot analysis ofIGF-binding proteins. Samples of conditioned medium from TC-1 murine bone marrow stromal cells and from Buffalo rat liver cells (kindly provided by Dr. N. Ross, University of California, Los Angeles) were electrophoresed through a 10% SDSpolyacrylamide gel. Separated proteins were electroblotted onto nitrocellulose filters and then incubated with ['25I]-IGF-I overnight at 4°C and visualized by autoradiography by the method of Hossenlopp (8, 35) .
Results
Serial dilutions of culture medium (5-200 y1) caused dose-dependent inhibition of ['25II-IGF-I binding to anti-IGF-I serum, with a pattern of inhibition similar to that observed with synthetic IGF-I (Fig. 1) . To exclude the possibility that IGF-I immunoreactivity in the conditioned medium represented carryover from the serum-containing medium, a time-course of the appearance of IGF-I immunoreactivity in serum-free, insulinfree medium conditioned by TC-1 cells was examined in the absence and presence of cycloheximide. In the absence of cycloheximide, IGF-I immunoreactivity (mean±SE) was 180 (mean of two experiments), 370±151, and 479±169 pg/105 cells at 8, 24 , and 48 h, respectively. Addition to the cultures of cycloheximide (10-s M, a concentration which did not affect cell viability as assessed by cell count and Trypan blue exclusion) resulted in a marked decrease (to less than the assay detection limit) in IGF-I immunoreactivity at each time point as compared with control wells, indicating that the presence of IGF-I immunoreactivity in the media is likely due to de novo protein synthesis.
Because IGFBPs in unextracted culture medium may alter apparent IGF-I immunoreactivity, we separated IGF-I from its To characterize further the nature ofthe IGF-I immunoreactivity in TC-l cells, we examined the expression of IGF-I mRNA with RNase protection assay using a complementary RNA probe derived from a genomic subclone ofrat IGF-I containing exon 3. The autoradiogram shown in Fig. 3 shows the predicted 182-bp fragment protected from ribonuclease digestion in lanes with aliquots ofpoly(A)+ RNA isolated from TC-l and the TC-1-C-II subclone of marrow stromal cells. Similar results were observed with both mouse and rat liver poly(A)+ RNA. No such species was observed with tRNA or probe alone. Because this method used a rat probe and because there are 10-bp differences between rat and mouse in this 182-bp exon, it appears that the RNase protection assay does not possess 100% specificity. Therefore, oligonucleotide primers based on the sequence ofexons 2 and 3 of mouse IGF-I mRNA were used to perform reverse transcription and polymerase chain reaction. Ethidium bromide staining ofthe amplified products subjected to electrophoresis, is shown in Fig. 4 . The predicted 250-bp fragment is observed; contamination ofthe initial sample with genomic DNA would result in an amplified fragment much larger in size.
Because the presence of IGFBPs might contribute to an apparent (albeit artifactual) increase in IGF-I immunoreactivity in the double-antibody RIA, we examined whether the higher molecular weight species identified by RIA of the gel filtration fractions possessed IGF-binding activity as determined by the charcoal adsorption assay. The peak ofIGF-binding activity in these high molecular weight fractions coeluted 1 2 34 ' i _ High-molecular weight fractions were assayed for IGF-binding activity by charcoal adsorption assay; the peak of IGF-binding activity coeluted with the peak of apparent IGF-I immunoreactivity. with the peak of apparent IGF-I immunoreactivity (Fig. 2) , suggesting that TC-l cells secrete IGF-binding protein(s). Because high molecular weight fractions derived from conditioned medium concentrated by octadecylsilane silica reverse chromatography, a method associated with low recovery of IGFBPS (1 1 ize the size distribution of IGF-binding species in conditioned medium Western ligand analysis was performed. As shown in Fig. 6 , three IGF-I binding species of -31, 38, and 40 kD were observed, whereas a single species of 31 kD was observed with conditioned medium from Buffalo rat liver cells, a source of IGFBP-2.
Discussion
IGF-I or somatomedin C is a biologically active growth factor with a wide variety of actions including stimulation of hematopoiesis (2-24, 36, 37) . The liver is the major source ofcirculating IGF-I. However, many of IGF-I's actions are paracrine in nature and depend upon local synthesis of IGF-I. Recent studies have demonstrated that a variety of mesenchymal cells synthesize or secrete IGF-I-like peptides and IGFBPs. Our data indicate that TC-l marrow stromal cells synthesize and secrete IGF-I and IGFBPs. Ofthe two species containing IGF-I immunoreactivity found in culture medium from these cells, one had an apparent molecular weight of 7.5 kD, the same size as native IGF-I, suggesting that this species is indeed IGF-I. The identification ofspecific IGF-I mRNA by RNase protection assay and reverse transcription polymerase chain reaction support the identification of the 7.5-kD immunoreactive IGF-I species as authentic IGF-I (38) .
In addition to the 7.5-kD IGF-I species detected in TC-l conditioned medium on gel filtration chromatography, a highmolecular weight species (> 25 kD) containing apparent IGF-I immunoreactivity was found. It is possible that this highermolecular weight species represents an IGF-I precursor which can be processed by proteolytic cleavage to yield IGF-I (1, 39). High-molecular weight forms of IGF-I have been observed in culture medium conditioned by human fibroblasts (6), macrophages (25) , and Sertoli cells (40) . However, the fact that the denaturing buffer (6 M guanidine HCI) used in the gel chro-matographic fractionation procedure dissociates IGF-I from its binding proteins and that the presence of IGF-binding species might result in an artificially high level of IGF-I immunoreactivity in the double antibody RIA raised the possibility that the high-molecular weight species might represent an artifact due to the presence of IGFBPs. The presence ofIGF-binding activity in these high-molecular weight fractions was confirmed by charcoal adsorption assay. Moreover, unfractionated conditioned medium exhibited IGF-binding activity with a pattern of affinity (IGF-I and IGF-II > insulin) characteristic of IGFBPs. Western ligand analysis ofTC-l conditioned medium demonstrated the presence of three IGF binding species of 31, 38, and 40 kD. The 1:4 ratio of IGFBP to the 7.5 kD IGF-I immunoreactive species in conditioned medium based upon denaturing gel filtration chromatography is an underestimate due to the low recovery ofIGFBPs from reverse phase chromatography (10). The coelaboration ofIGF-I and IGFBP by TC-I cells has been observed with other cell types (7, 8, 41, 42) . Three major IGFBPs have been described-BP1, BP2, and BP3-in both the human and rat (12, 13) . The 1 50-kD IGFBP complex in serum dissociates into IGF, an acid-labile component without affinity for IGFs, and a 53-kD IGFBP, a glycosylated form of BP3. Recently, additional IGFBPs have been identified (43, 44) . The physiological importance of IGFBPs remains to be clarified. Specific binding in serum protects IGF-I from proteolytic degradation and prolongs its half-life (10, 12). In some systems, IGFBPs inhibit the action of IGF-I (42, 45-47) whereas in others they enhance IGF-I's action (47, 48) or appear to be bioactive in the absence of IGF-I (49) Growth hormone and IGF-I play an important role in hematopoiesis. Whereas both growth hormone and IGF-I enhance human marrow erythroid and granulocytic progenitor cell growth in vitro (20-24, 36, 37), the effect of growth hormone requires the presence of adherent cells and is abrogated by monoclonal antibodies directed against IGF-I membrane receptors (22, 24) . Although the precise cellular origin ofIGF-I is unclear, monocytes from the marrow adherent layer have been implicated as the source ofIGF-I, because these cells were required for stimulation of erythropoiesis or granulopoiesis by growth hormone. In these cultures, IGF-I did not appear to induce the production of hematopoietic factors from accessary cells nor did it replace erythropoietin or colony-stimulating activity. However, recent studies, using highly purified colonyforming units erthyroid (CFU-E), demonstrated that physiologic concentrations ofIGF-I directly enhanced CFU-E growth and was not dependent on the presence of accessory cells (37) . Whereas marrow macrophages may constitute a source ofIGF-I, the results of the present study clearly demonstrate that marrow stromal cells constitute another potential source ofthis peptide. IGF-I released by stromal cells may act in concert with other hormones and cytokines such as erythropoietin in the regulation of hematopoiesis. In addition, the release of IGFBP by stromal cells may modulate the effects of IGF-I within the marrow microenvironment. Although the precise biologic role of IGF-I and IGFBP secreted by stromal cells remains to be determined, the TC-l cells provide a valuable model to study further the regulation of IGF-I and IGFBP production and their interactions.
